Evaluation of DTRAX Graft in Patients With Cervical Degenerative Disc Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94114
- Office of Dr. Brian Andrews, Neurosurgery
-
San Francisco, California, United States, 94115
- Neurospine Institute Medical Group
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subject diagnosed with DDD in C3-C7, defined as follows:
Radiographically (at least one):
- degenerated disc on MRI;
- decreased disc height on plain film, CT or MRI; and/or
- disc herniation, as demonstrated by CT or MRI.
Clinically: radicular symptoms (at least one):
- arm/shoulder pain;
- decreased reflexes;
- decreased strength; and/or
- decreased sensation.
Subject has single-level disease, OR multi-level disease demonstrated radiographically, and confirmed to be symptomatic by one of the following methods:
- Selective nerve root block, OR
- EMG, OR
- Distinctive clinical examination.
- Subject has dynamic stenosis relieved by traction and made worse by a Spurlings maneuver.
- Subject is 35-80 years of age, inclusive.
- Subject is unresponsive to 6 weeks conservative, nonoperative treatment, or has the presence of progressive symptoms or signs of nerve root compression in face of combined nonoperative management.
- Preoperative NDI score of ≥ 30.
- Preoperative neck pain and arm pain score of ≥ 6 on Neck and Arm Pain Scales.
- Patient is a male or non-pregnant, non-lactating female.
- Female patients of child-bearing potential, including those who have had a tubal ligation, but excluding those who have not experienced a menstrual period for at least two years, must have a negative urine pregnancy test at Screening.
- Patient must voluntarily provide written, informed consent.
- Subject is able to meet the proposed follow-up schedule.
- Subject is able to follow the postoperative management program.
Exclusion Criteria:
- Subject has severe osteopenia, osteoporosis, osteomalacia, spinal metastases, or metabolic bone disease OR the level of BMD is a T score of -2.5 or below OR patient has sustained a vertebral compression or nontraumatic hip or wrist fracture.
- Subject has overt or active spinal and/or systemic infection.
- Subject has spondylolisthesis ≥ 3.5mm or rotator subluxation.
- Subject has cervical myelopathy.
- Subject has a chronic pain syndrome.
- Subject has radicular findings with major motor impairment.
- Subject has a condition that requires postoperative medications that interfere with fusion or the stability of the implant, such as steroids.
- Subject is mentally incompetent.
- Subject is a prisoner.
- Subject is pregnant.
- Subject abuses alcohol or drugs.
- Subject has a cervical spinal condition other than symptomatic cervical disc disease requiring surgical treatment at the involved level.
- Subject has insulin dependent diabetes.
- Subject has chronic or acute renal failure or prior history of renal disease.
- Subject has fever at the time of surgery, defined as > 38.5 degrees C.
- Subject has documented allergy or intolerance to stainless steel, titanium, or a titanium alloy.
- Subject has received drugs which may interfere with bone metabolism within two weeks prior to the planned date of DTRAX surgery.
- Subject has history of an endocrine or metabolic disorder known to affect osteogenesis .
- Subject has had treatment with an investigational therapy within 28 days prior to DTRAX surgery or such treatment is planned during the 16 weeks following implantation of DTRAX Graft.
- Subject is involved in spinal litigation or Workmen's Compensation claim.
- Subject is obese, defined as body mass index (BMI) > 35.
- Patient has psychiatric history, head injury or any other condition, which, in the Investigator's opinion, would prevent the patient from complying with postoperative follow-up visits.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: DTRAX graft
|
DTRAX Graft is an allograft implant inserted to support spinal fusion.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gather clinical outcome data on DTRAX Graft.
Time Frame: Baseline throughout 12 months post-operatively
|
Clinical outcome data will be collected using the Neck Disability Index (NDI), Visual Analogue Scale (VAS), and a quality of life questionnaire.
|
Baseline throughout 12 months post-operatively
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Safety information will be evaluated by collecting the type, frequency, severity, device, and procedure-relatedness of adverse events.
Time Frame: Baseline throughout 12 months post-operatively
|
Baseline throughout 12 months post-operatively
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Bruce McCormack, M.D., Neurospine Institute Medical Group
- Principal Investigator: Brian Andrews, M.D., Office of Dr. Brian Andrews, Neurosurgery
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PMT002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.